1. JNJ shareholders urged to reject CEO's $30M payday — Abbott profits triple as OTC COVID-19 tests hit shelves — Vertex puts a blockbuster valuation on its CRISPR deal See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Edit Tags: Shortchanged on Performance Evaluation

Multiple tags may be separated by commas.